Scientists Close In on Hepatitis B Cure for 254M People

For millions living with chronic hepatitis B, the message has always been the same: you'll need treatment for life. Now, scientists across Europe are proving that doesn't have to be true.

Professor Ulrike Protzer at the Technical University of Munich calls hepatitis B "the most frequent neglected disease in the world." She's right to sound urgent. The virus quietly infects 254 million people worldwide and causes 1.1 million deaths each year from cirrhosis and liver cancer.

The cruel irony is that we've had a prevention vaccine for over 40 years. But for people already infected, current medicines only suppress the virus without eliminating it. Stop treatment, and the infection roars back.

Protzer is leading the TherVacB initiative, developing something entirely different: a therapeutic vaccine for people already living with chronic infection. Instead of attacking the virus directly, her team is training patients' immune systems to fight back the way healthy people naturally do.

The vaccine recreates the powerful antibody and T-cell responses seen in people who naturally clear hepatitis B after infection. Early trials in healthy volunteers went well, and patient trials are now underway in Germany, Italy, Spain, the UK and Tanzania.

Meanwhile, another EU-funded team called IP-cure-B just completed their Phase IIa clinical trial with a different approach. Led by Professor Fabien Zoulim at Claude Bernard University Lyon 1, they're exploring whether "waking up" the immune system before stopping antiviral medicines lets patients stay healthy long-term.

Dr. Maria Butí Ferret, a hepatologist at Hospital Universitari Vall d'Hebron in Barcelona, has treated hepatitis B patients for decades. She's never been more optimistic.

"We are entering a very exciting time in hepatitis B research," she said. "The future will probably not come from a single treatment, but from combining different approaches that work together."

That's the key shift in scientific thinking. Researchers no longer believe one magic bullet will cure hepatitis B. Instead, combination therapies targeting different parts of the virus and boosting immune response will work together to achieve a functional cure.

The Ripple Effect goes far beyond the 254 million currently infected. In the EU alone, 3.6 million people live with chronic hepatitis B, many unaware until serious liver damage occurs. A functional cure would mean no more lifelong treatment, no more daily pills, no more worry about the virus returning.

It would also bring the World Health Organization closer to its 2030 goal of eliminating viral hepatitis as a public health threat. Wider vaccination prevents new infections, but only a cure can help the hundreds of millions already living with the disease.

The researchers caution their work remains in early clinical stages. But after decades of telling patients they'd need treatment forever, doctors are finally saying something different: hope is real, and a cure may be within reach.